

2009 Program Faculty

Peter Libby, MD – Program Co-Chair,
Mallinckrodt Professor of Medicine
Harvard Medical School

Jean-Claude Tardif, MD – Program Co-Chair
Director, Research Center
Montreal Heart Institute

Donald M. Black, MD, MBA, Global Head R&D,
GE Healthcare

Melanie Blank, MD, Medical Officer, CDER, US
FDA

Eric P. Brass, MD, PhD, Prof of Med, Harbor-
UCLA Medical Center

Eugene Braunwald, MD, Professor of Medicine,
Harvard Medical School

Robert Califf, MD, Director, Duke Translational
Medicine Institute

Laure Cloarec-Blanchard, MD, Servier Interna-
tional

Helen Colhoun, Professor of Public Health, Uni-
versity of Dundee, Scotland

Marcelo Di Carli, MD, Chief, Nuclear Medicine,
Brigham and Women's Hospital

Benjamin Eloff, PhD, Office of the Commis-
sioner, US FDA

Zahi A. Fayad, PhD, Prof of Med, Mount Sinai
School of Medicine

Jean-Jacques Garaud, MD, Head of Global Drug
Dvpt., F. Hoffmann-La Roche

Mark Grant, MD, Tech Evaluation Center, Blue
Cross Blue Shield Association

Therese Heinonen, DVM, Exec. Director, CMOD,
Assoc. Director MHICC

Karen A. Hicks, MD, Medical Officer, CDER, US
FDA

Hylton Joffe, MD, Metabolism and Endocrine,
CDER, US FDA

Dominique Johnson, PhD, Director, MHICC

Agnes Klein, MD, Ctr for Eval of Radiopharm
and Biotherapeutics, Health Canada

Wolfgang Koenig, MD, Prof of Med and Cardi-
ology, U of Ulm Medical Center

Gina Kolata, Science and Medicine Reporter,
New York Times

Peter Liu, MD, Scientific Director, Canadian
Institutes of Health Research

George A. Mensah, MD, Centers for Disease
Control and Prevention

George Mills, MD, VP, Medical Imaging Con-
sultant, Perceptive Informatics

Irene Nunes, OD, PhD, Merck Research Labo-
ratories

Oye Olukotun, MD, CEO, CardioVax Inc.

Mary Parks, MD, Director, Metabolism and
Endocrine, CDER, US

Joel Raichlen, MD, Senior Director, Astra-
Zeneca

Gurvaneet Randhawa, MD, Agency for Health-
care Research and Quality

Paul M. Ridker, MD, Professor of Medicine,
Brigham and Women's Hospital

Dwaine Rieves, MD, Director, Medical Imaging
and Hematology, CDER, US FDA

Norman Stockbridge, MD, Director, Cardio-
renal, CDER, US FDA

Anders Svensson, MD, Head, Clinical Develop-
ment, Metabolism, F. Hoffmann-La Roche

Ahmed Tawakol, MD, Professor of Medicine,
Massachusetts General Hospital

Robert Temple, MD, Director, Office of Medi-
cal Policy, US FDA

Douglas C. Throckmorton, MD, Deputy Direc-
tor, CDER, US FDA

Gerald Willett, MD, Reproductive and
Urologic Drug Products, CDER, US FDA

David Waters, MD, University of California,
San Francisco

Samuel Wright, PhD, Director, Cardiovascular
Therapeutics, CSL Ltd.

7th Annual CMOD

Biomarkers and Surrogate Endpoints Symposium

Bethesda North Marriott Hotel
and Conference Center
5701 Marinelli Rd
Rockville, MD 20852
(301) 822-9200

October 19- 21, 2009
Bethesda, Maryland



**Streamlining to Promote
Innovation and Efficiency”**

**This meeting has been organized in collaboration with
representatives from:**

US Food and Drug Administration (FDA)
National Institutes of Health (NIH)
Centers for Disease Control and Prevention (CDC)
US Agency for Healthcare Research and Quality (AHRQ)
Health Canada (HC)
Canadian Institutes for Health Research (CIHR)
Society Nuclear Medicine (SNM)
Radiology Society of North America (RSNA)
and other public and private research organizations.

For More information please visit www.cmod.org

CMOD Mission:

The mission of the international Partnership for Critical Markers of Disease (CMOD) is to accelerate the identification, validation and appropriate application of biomarkers in cardiovascular and related diseases.

Goal:

To create efficiencies toward improved patient healthcare. Toward this goal the partnership works to:

1. Provide scientifically rigorous and balanced information on established and novel biomarkers and imaging technologies;
2. Facilitate the cooperative exchange of ideas and information about critical biomarkers among clinical and basic scientists, governmental regulatory agencies, pharmaceutical, biotech and diagnostic companies, healthcare providers and patient groups;
3. Identify issues in biomarker identification and offer educational programs which provide access to the most current information on biomarker and related sciences to meet educational needs;
4. Promote and support collaborative initiatives to advance the identification, validation and application of biomarkers most efficiently.

Agenda for: **October 19 - 21, 2009 Bethesda, Maryland**

Monday 1-6PM

Session 1

Biomarker innovations enabling drug and diagnostic development

Description: Individual experts will provide an overview of promising research across disease states, including the use of proteomics, genomics, and metabolomics. Industry representatives will provide examples of commercial applications of novel technologies.

Tuesday 8AM-3PM

Session 2

Regulatory Roundtable: How can biomarkers streamline the regulatory process?

Description: Representatives from FDA and Health Canada will provide their insights regarding the utility of biomarkers for use in drug development. This session will highlight recent controversies and provide examples of challenges, progress and ongoing efforts in this area.

Tuesday 3-6PM

Session 3

Streamlining clinical trials and communications

Description: Focusing on recently completed, and ongoing, large-scale cardiovascular clinical trials, the use of biomarkers will be reviewed and debated by experts in drug development, clinical trial design, translational medicine, economics, epidemiology and public health. Additionally, the need to accurately and effectively communicate clinical trial results to the medical community and the general public will be examined.

Wednesday 8AM-12PM

Session 4

Medical Imaging Update

Description: Imaging technologies have been pivotal in elucidating the mechanism behind cardiovascular and related diseases, as well as assessing the effectiveness of therapeutic intervention. This session will highlight the state of the art imaging technologies and their application in research and clinical practice settings. Industry representatives will provide examples of commercial applications of novel technologies.

Wednesday 12- 4PM

Session 5

Molecular Imaging Workshop (co- sponsored by SNM and RSNA)

Description: Technological advances have empowered molecular imaging methods to elucidate pathophysiology, treat diseases and monitor therapeutic response. Advances in molecular imaging and the associated regulatory challenges will be examined by representatives from FDA, industry, academia, and professional societies.

Visit www.cmod.org for
information & registration